US Private Payers Could Build Evidence On Alzheimer’s Drugs With Outcomes-Based Contracts

 
• By Cathy Kelly

Value-based contracting advocate Michael Sherman suggests creating an ‘enormous risk-based agreement as an industry’ between commercial payers and manufacturers of Alzheimer’s drugs that would condition reimbursement on achieving certain clinical endpoints.

Alzheimer's brain money
Payers Wary Of Biomarker-Driven Approvals For High-Cost Drugs • Source: Nielsen Hobbs; the Pink Sheet | Alamy images

More from Pricing Debate

More from Market Access